Related coverage linked through entity extraction aliases.
Feb 19, 2026
Phase 3 LATITUDE trial shows monthly cabotegravir-rilpivirine injections cut regimen failure risk by 18.4 percentage points compared to daily oral ART in HIV patients with documented adherence difficulties.
Feb 15, 2026
The FDA agreed to review Moderna's mRNA flu vaccine application after initially rejecting it, reversing course within a week. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and above, with a decision expected by August 5.
Feb 13, 2026
An international research team has identified antibody 007, which targets HIV-1's V3 glycan site without depending on sugar structures the virus frequently alters, remaining effective against resistant variants and enhancing combination therapies.
Feb 13, 2026
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
Feb 12, 2026
President Trump signed a spending package funding the National Institutes of Health at nearly $49 billion, the highest level ever, reversing his earlier push for a 40% budget cut to medical research.
